Yes, Orion Peptides offers bulk wholesale purchasing for researchers needing larger volumes of research-grade peptides. What Bulk Typically Means: - Larger vial quantities (10–100+ vials) - Higher milligram amounts (50mg, 100mg+) - Custom synthesis projects How to Inquire: 📧 Email:[email protected] 🌐 Website:OrionPeptide.com Provide: 1. Specific peptide(s) 2. Quantity needed 3. Timeline & purity requirements Key Considerations: - Batch-specific COAs available for verification - Strictly for laboratory research & in-vitro testing - Ensure compliance with institutional guidelines 🔬 For research-grade peptides in bulk, check OrionPeptide.com. ⚠️ Research only. Not for human consumption.

What Is Category 2? FDA classification for bulk drug substances with potential safety risks. Compounding isnot permitted. 19 Peptides Affected (Late 2023) BPC-157, TB-500, KPV, MOTS-C, Semax, Epitalon, GHK-Cu (injectable), Melanotan II, CJC-1295, Ipamorelin, Thymosin Alpha-1, and others. Recent Developments (2026) Feb 27, 2026 – RFK Jr. Announcement - Stated ~14 of 19 Category 2 peptides would move back to Category 1 - Called the 2023 reclassification "illegal" April 15, 2026 – FDA Action - 12 peptide bulk substances removed from Category 2 - ⚠️ Critical: Removal ≠ authorization to compound - Peptides remain in regulatory uncertainty July 23–24, 2026 – PCAC Meeting FDA committee to discuss adding 7 peptides to the 503A Bulks List: Day 1 (July 23): - BPC-157 (ulcerative colitis) - KPV (wound healing) - TB-500 (wound healing) - MOTS-C (obesity, osteoporosis) Day 2 (July 24): - Emideltide/DSIP (opioid withdrawal, insomnia) - Semax (cerebral ischemia, migraine) - Epitalon (insomnia) Feb 2027 – Second PCAC Meeting Cathelicidin (LL-37), GHK-Cu, Dihexa acetate, Melanotan II, PEG-MGF What This Means for Researchers - PCAC recommendations are advisory only - FDA retains final authority - Rulemaking takes 12–24+ months - No formal rule change finalized yet - Access remains primarily through research suppliers Takeaway Regulatory process is ongoing. Removal from Category 2 ≠ compounding authorization. PCAC review will shape future access. 🔬 For research-grade peptides, check OrionPeptide.com. ⚠️ Research only. Not for human consumption.

The Evolution - Semaglutide (GLP-1): ~15% weight loss - Tirzepatide (GLP-1/GIP): ~21% weight loss - Retatrutide (GLP-1/GIP/Glucagon): rivals bariatric surgery The Data - Phase 2 (12 mg): 24.2% weight loss at 48 weeks; 64% achieved ≥20% - Phase 3 TRIUMPH-4: 28.7% (71.2 lbs) at 68 weeks; 58.6% achieved ≥25% - Network meta-analysis: 3.2% greater than tirzepatide, 9.9% > semaglutide Beyond Weight Loss - HbA1c reduction: 2.16% at 36 weeks; 82% reached ≤6.5% - Knee osteoarthritis pain: WOMAC reduction of 4.5 points - 82% reduction in hepatic steatosis - Blood pressure, lipids, and liver fat improvements - Preclinical: 14-fold reduction in pancreatic tumor volume Safety - GI side effects (nausea, diarrhea, vomiting) - Discontinuation rate (12 mg): 18.2% - Higher adverse event risk than dual agonists Takeaway Retatrutide represents a significant advancement in metabolic research. Triple agonist mechanism offers synergistic benefits. 🔬 For research-grade retatrutide & other peptides, check OrionPeptide.com. ⚠️ Research only. Not for human consumption.

The Core Dispute - U.S. Patent No. 8,129,343 (expires 2030s) covers semaglutide's molecular structure - Feb 2026: Novo Nordisk sued Hims & Hers over compounded semaglutide infringement - First patent-infringement lawsuit between brand manufacturer & compounding pharmacy International Challenge - Dec 2025: Delhi High Court refused injunction against Dr. Reddy's - Court found patent "prima facie vulnerable" - Generic oral semaglutide launched in India (April 2026) → 40% volume increase Patent Expiration - Primary U.S. patents expire early 2030s - No FDA-approved generic yet - Generic launch typically 6–12 months post-expiration The Legal Gray Zone - Compounding exemptions don't automatically shield from patent claims - Two separate questions: FDA rules vs. patent rights Implications for Researchers - Compounded products may be subject to patent infringement - Access barriers until generics arrive - Research-grade peptides require transparent sourcing 🔬 For research-grade peptides, check OrionPeptide.com. ⚠️ Research only. Not for human consumption.

The Scale of the Crisis - 40%+ US adults live with obesity - $170–260B annual direct medical costs - Broader economic & societal costs far higher Cost-Effectiveness - ICER: GLP-1s meet cost-effectiveness thresholds - Tirzepatide: ~$53K/QALY - Semaglutide: ~$61K/QALY - However, potential users create $100B+ annual spending Do They Pay for Themselves? 2026 NBER analysis: No reduction in downstream medical spending. Non-GLP-1 spending increases (outpatient care). Cost savings likely only over longer horizons or through non-medical channels. Societal Perspective 50% treatment of obesity class II/III: - Reduces obesity prevalence by ~33% - Reduces class II/III expenses by 12.9% (€108.7M) - ~40% cost reduction per patient over life cycle Government Approaches - 🇦🇺 Australia: PBS listing for BMI≥35 (or ≥32.5 for certain ethnicities), slow roll-out, price reduction required - 🇬🇧 UK: Funded for BMI≥30 (1 comorbidity) since 2023; Mounjaro for BMI≥35 (limited to 220K patients) - 🇺🇸 US: MFN policy at $245/month → $73.9B Medicare spend over 10 years. Cost neutrality at ~$150/month Global Equity - WHO updated essential medicines list to include GLP-1RAs - Annual cost >$8K puts them out of reach for most LMICs Challenges - Long-term benefit tracking (up to 10 years) - Risk of malnutrition & muscle loss - Could worsen diet culture & fat phobia Takeaway: GLP-1s are clinically & societally beneficial but don't yet pay for themselves. Governments likely to pursue selective subsidization: targeting highest-risk patients, negotiating lower prices, and implementing managed access. 🔬 For research-grade peptides, check OrionPeptide.com. 🎉 20% OFF Sitewide—Discount Automatically Applied at Checkout ⚠️ Research only. Not for human consumption.